Catalyst Pharmaceuticals (CPRX) Tax Provisions (2019 - 2026)

Catalyst Pharmaceuticals (CPRX) has 8 years of Tax Provisions data on file, last reported at $20.5 million in Q1 2026.

• Quarterly Tax Provisions rose 40.87% year-over-year to $20.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.5 million (up 7.16% YoY) and the FY2025 annual result came in at $59.5 million, up 13.68% from the prior year.
• Tax Provisions climbed to $20.5 million in Q1 2026, from $9.6 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $29.7 million in Q4 2023 to a low of -$7.3 million in Q3 2023.
• A 5-year average of $11.5 million and a median of $10.8 million in 2023 frame the typical range for Tax Provisions.
• The widest YoY moves for Tax Provisions: up 293.63% in 2023, down 322.68% in 2023.
• Tracing CPRX's Tax Provisions over 5 years: stood at $7.5 million in 2022, then soared by 293.63% to $29.7 million in 2023, then slumped by 38.5% to $18.2 million in 2024, then sank by 47.65% to $9.6 million in 2025, then soared by 114.56% to $20.5 million in 2026.
• The last three Tax Provisions figures came in at $20.5 million (Q1 2026), $9.6 million (Q4 2025), and $18.3 million (Q3 2025), per Business Quant data.